Medical Device Maker Nocollagen Biologic Renews Hong Kong IPO Bid

Nanjing Nocollagen Biologic Co., Ltd., a Chinese medical technology firm focused on cardiopulmonary devices, has renewed its bid for a public listing by submitting a new application to the Main Board of the Hong Kong Stock Exchange (HKEX).

Renewed Listing Application

According to an official disclosure filed with the exchange on August 28, Nocollagen Biologic is moving forward with its initial public offering plans. The filing confirms that CCB International is acting as the sole sponsor for the transaction. The financial terms of the proposed offering were not disclosed.

This submission marks a refiling for the company, indicating a renewed effort to list its shares on the prominent Asian exchange, a key venue for healthcare and biotechnology firms seeking capital.

Business Focus and Product Pipeline

Ad

Founded in 2018, Nocollagen Biologic operates in the gas-based cardiopulmonary therapy market. The company's core business is the research, development, and commercialization of inhaled nitric oxide (iNO) therapy.

As detailed in its prospectus, the company has a portfolio that spans various stages of development and commercialization:

• 5 approved products, including its core product, an iNO therapy system named iNOwill.
• 5 product candidates currently in its development pipeline.

The company's strategy covers a wide range of clinical and home-care settings, including critical care, hospital wards, outpatient clinics, and at-home disease management. Its offerings are organized into three main product lines: iNO therapy, cardiopulmonary circulatory support, and exhaled breath diagnostics.